Molecularly targeted agents for renal cell carcinoma: the next generation.
Clin Adv Hematol Oncol
; 8(5): 357-60, 361-4, 2010 May.
Article
em En
| MEDLINE
| ID: mdl-20551895
With the approval of several molecularly targeted agents over the past few years, the landscape of renal cell carcinoma (RCC) management has drastically changed. Response rates and survival have improved with these new agents compared to the previous standard of cytokine-based therapy. Many new agents are in various stages of development, and how these novel therapies will be incorporated into the paradigm of RCC treatment is yet to be determined. The development of optimal sequencing and combinations of these drugs is important to improving patient outcomes and overcoming resistance mechanisms.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Carcinoma de Células Renais
/
Proteínas Serina-Treonina Quinases
/
Fator A de Crescimento do Endotélio Vascular
/
Peptídeos e Proteínas de Sinalização Intracelular
/
Inibidores de Proteínas Quinases
/
Neoplasias Renais
/
Antineoplásicos
Limite:
Humans
Idioma:
En
Ano de publicação:
2010
Tipo de documento:
Article